

**REVIEW PAPER**

# Endometriosis as female reproductive system disorder: mechanisms, diagnosis and clinical management

Mahta Bagheri <sup>1</sup>, Fateme Zohre-Vand <sup>1</sup>, Mahya Hamzeie <sup>2</sup>, Babak Arji Roudsari <sup>2\*</sup>

<sup>1</sup> Member of Research Committee, Medical School, Hamedan University of Medical Sciences, Hamedan, Iran


<sup>2</sup> Department of Anatomical Sciences, Medical School, Kermanshah University of Medical Sciences, Kermanshah, Iran



**Highlights**

- Endometriosis is a chronic and inflammatory gynecological disease that affects 10% of women populations.
- Various factors such as environmental and genetic factors and hormonal factors can change the endometriosis risk.
- Painkillers and contraceptive hormones are appropriate ways for endometriosis treatment.

**Graphical Abstract**



**Article Info**

**Receive Date:** 20 February 2021

**Revise Date:** 03 June 2021

**Accept Date:** 30 July 2021

**Available online:** 05 August 2021

**Keywords:**

- Endometriosis
- Inflammation
- Genetic factors
- Hormone therapy
- Disease management

**Abstract**

Endometriosis is a gynecological, chronic, and inflammatory disease affecting one out of ten women globally. It occurs when tissues similar to the endometrial layer of the uterus grow outside the uterine body leading to inflammation, pain, and infertility. The most common site of endometriotic lesions is pelvic cavity, especially the ovaries. Thus, at the same time as menstruation, these points initiate bleeding, which results in many difficulties. Several mechanisms of endometriosis have been suggested, such as retrograde menstruation, the influence of environmental and genetic factors, and hormonal causes. In some cases, this pathologic condition occurs following pregnancy or pelvic surgery. Disease management also involves the use of painkillers and contraceptive hormones for a relatively long time or even the use of laparoscopy to remove the pathologic lesions. In this review, the mechanisms of endometriosis were discussed, as well as various aspects of the disease in the field of diagnosis and treatment were assessed.

© 2021 Published by CAS-Press.



## Introduction

Endometriosis is a common, chronic, and benign disorder in women, which refers to the growth of endometrial tissue outside the uterus like ovaries, uterosacral ligaments, and the pouch of Douglas (1). Sometimes endometriosis occurs in extra-genital sites, such as diaphragmatic pleural or umbilical lesions (2). Endometriosis affects 20-50% of infertile women and 6-10% of women of reproductive age, and 70% of women with chronic pelvic pain (3). It is a hereditary hormone-dependent disease that is associated with inflammation, pelvic pain, and infertility. Endometriosis has an inherited pattern. First-degree relatives of people with endometriosis are 6-9% more likely to develop the disease than normal people. Also, this type of disease comprises 15% of all severe diseases. On the other hand, the prevalence and age of onset of this disease are the same in twin sisters. Researches showed that heredity is 50% of all endometriotic cases, even in women who underwent hysterectomy (4).

There is no definitive cause for the pathophysiology of endometriosis, but various risk factors include several genetic and environmental aspects that are effective. Shorter menstrual length, menstruation at young ages, taller height, high body mass index (BMI), and smoking are risk factors (5). After the invention of the laparoscopy procedure in the 1970s, endometriotic lesions were safely diagnosed in women with pain and infertility (4). Superficial peritoneal lesions, ovarian endometrioses, and deep infiltrating endometriosis are three well-recognized phenotypes of endometriosis (Figure 1A). Deep infiltrating endometriosis is the most severe type, which penetrates to a depth of more than 5 mm beneath the peritoneal surface or as lesions in the muscles of the organs surrounding the uterus. The American Reproductive Medicine Association (ARMA) categorized endometriosis into 3 stages; severity, type, and location of the lesions. Finally, in high grades of endometriosis, surgery is strictly recommended (6).

Although endometriosis is a progressive disease, the lesions, intense rectovaginal lesions, showed non-rapid growth. Also, the recurrence rate of the lesions after their complete removal was very low (4). Nonetheless, this disease has many negative consequences on daily life, personal relationships and sexual function, and unfortunately, due to the late diagnosis, women with endometriosis usually have severe pelvic pain for a long time. Also, because this disease is one of the main causes of female infertility, it is essential for women's health. Thus, it should be seen as a social health problem, not an individual disorder (7). In this study, we narrate the mechanisms involved in the pathogenesis of endometriosis, its diagnosis and effective treatment strategies.

## Possible pathophysiology mechanisms of endometriosis

Among the mechanisms suggested for endometriosis, retrograde menstruation is the most accepted hypothesis, which refers to the condition in which blood from the discharge of the endometrial layer of the uterus returns to the pelvis and fallopian tubes instead of the vaginal canal. In this case, it can implant, develop and sometimes attack other pelvic tissues (6). Endometriotic lesions often have an asymmetrical distribution. More lesions in the pelvis are seen in the posterior chamber and on the left, while lesions in the abdomen and thorax are on the right site (8). Other mechanisms involved in this disease include unregulated immunity, inflammatory factors, hormones, genetic and epigenetic factors, and environmental causes. They may also have pre-existing endometrial abnormalities, which lead to pathological endometrial implantation and growth out of the uterus (9).

Genes play an essential role in transmitting the disease from one generation to another. Although the specific gene pattern involved in endometriosis has not been established, many genes can be attributed to endometrial involvement, including genes of cell cycle regulation, inflammation, hormone receptors, growth factors, and adhesion molecules (10). Genetic mutations may interact with other factors, including changes in hormonal hemostasis. They can also be tissue-specific or affect other gene expressions in different tissues (11). Various studies have shown that two chromosomal regions 10q26 and 7p13-15 have some crucial genes such as CYP2C19, INHBA, SFRP4, and HOXA10 have a significant role in the transmission of hereditary endometriosis to the next generation (12). Environmental factors such as endocrine-disrupting chemicals are other influential

factors in endometriosis. There is currently no direct evidence of the role of endocrine-disrupting chemicals in endometriosis (13).

Other causes of endometriosis include surgery, hormone therapy, pregnancy, and ovarian stimulation during infertility treatment which may cause by chronic stress, activation of adrenergic pathways, and increased rate of angiogenesis (9). The role of estrogen in endometriosis development has also been well established; the secretion of estradiol by endometriotic lesions in the peritoneal cavity creates a precise endocrine substrate for implantation of many lesions (14). However, another study has shown that the growth of lesions outside the uterus has not continued even in environments with high estrogen levels. Thus, it can be stated that the presence of estrogen is necessary and not sufficient to cause endometriosis (15). Other cases of endometriosis include its postmenopausal development, which is probably due to the production of extra-ovarian estrogen by endometriotic lesions and adipose tissue (16).

### Endometriosis-related Infertility


Several factors are involved in both endometriosis and infertility. Thus, there are different reasons to explain why endometriosis can cause infertility. The type and quality of the relationship between endometriosis and infertility should also be evaluated for effective treatment procedures. In one study, changes in pelvic density, immunological system, and endometrial alterations in baboons with spontaneous endometriosis were associated with infertility. As infertility was also observed in these baboons, possibly it is related to ovulation dysfunction. Research has also shown that fertility rates will decrease more sharply in baboons with moderate to severe endometriosis than in those with mild endometriosis (17).

This disease can adversely affect fertility due to inflammatory changes in the pelvic cavity, ovaries, and uterus, leading to ovarian dysfunction, fertilization changes, uterine endometrial abnormalities, pelvic adhesions, and decreased frequency of sex due to pain (18). In addition, adenomyosis, which is often associated with endometriosis, is also involved in infertility. Adenomyosis is a disease in which the endometrium breaks through the myometrium, causing menstrual cramps and low abdominal pressure and leading to heavy blood discharge (19).

Human endometrium decidualization involves a dramatic functional and morphological differentiation of human endometrial stromal cells (ESCs) and is crucial for forming an effective pregnancy. Decidualization results from a complex interplay of morphogens, transcription factors, cell cycle regulators, cytokines, and signalling pathways. Together with proteins regulated by progesterone and/or cyclic adenosine monophosphate, progesterone procedures a crucial network for decidualization of ESC and is a prerequisite to successful implantation. Decidualized ESCs involve in the microenvironment at the fetomaternal interface and its indirect or direct effect on extracellular matrix remodelling, anti-oxidative stress, the local immune response regulation, and angiogenesis. Damage of this procedure is related to some pregnancy disorders, including recurrent miscarriages, infertility, and uteroplacental disorders (20).

### Endometriosis-related Pain

There are several mechanisms of pain in endometriosis in which the presence of endometrial cells following retrograde menstruation is considered the leading cause of pain. After implantation of endometriotic lesions in the pelvis, the immune cells (macrophages, mast cells, neutrophils, natural killer cells, dendritic cells, and B and T lymphocytes) in the peritoneal fluid are stimulated to large secret volumes of multiple types of cytokines (TNF- $\alpha$ , IL-10, and TGF- $\beta$ ), chemokines (IL-8), angiogenic growth factors (VEGF), and alarmin (IL-33) (21,14). Endometriotic lesions localized next to nerve fibers lead to continuous stimulation and pain production. Also, peripheral nerves are constantly stimulated, and chronic pelvic pain is seen (6). Excessive generation of prostaglandins and inflammatory factors by endometriotic lesions can also lead to myometrium hypertonia and secondary ischemia resulting in dysmenorrhea (Figure 1B). Thus, it is recommended to treat endometriosis pain as soon as possible to prevent further pathologic events (22).



**Figure 1.** Overview of endometriosis and involved inflammatory factors; A) Superficial peritoneal lesions, ovarian endometrioses, and deep infiltrating endometriosis are three well-recognized types of endometriosis due to the origin of lesions. B) Retrograde menstruation is the most important mechanism involved in endometriosis development which is caused by the return of menstrual blood into the fallopian tubes and pelvic cavity. After implantation and adhesion of endometriosis lesions in the pelvic cavity, immune cells are activated and induce pain by secreting various cytokines, chemokines, and immune factors.

## Diagnosis

The process of endometriosis diagnosis has always been faced with many difficulties. Symptoms of the disease are general; thus they cannot be definitively attributed to the disease. In addition, the pathogenesis of endometriosis is always an ambiguous process. On the other hand, the disease has three different phenotypes in which their simultaneous occurrence makes the diagnosis process more difficult. In some cases, endometriosis co-occurs with adenomyosis complicates the diagnosis and treatment of this disease. However, the main problem in diagnosing endometriosis is pelvic pain as the primary symptom, which appears in different forms. It is also sometimes associated with other non-gynaecological problems, such as gastrointestinal or urinary tract pain, which can confuse specialists (23, 24). As a result, specialists face a severe challenge in definitively diagnosing endometriosis. Most patients do not show a specific sign during the pelvic and uterine examination, and the diagnosis is usually made by asking questions about the person's clinical history.

Regarding the difficulties in diagnosing pelvic involvement in endometriosis, it is essential to state that the patient must be evaluated for other pelvic involvements. Thus, to make a definitive diagnosis, ultrasound scans should be performed to ensure the absence of fibroids and ovarian cysts. It is also better to perform pregnancy tests; Pap smears sampling, urine analysis and cell culture, as well as vaginal and cervical sampling (5, 25).

Ultrasonography of pelvic masses is performed in both trans-vaginal and trans-abdominal. Transvaginal ultrasonography provides a better image of pelvic space to detect ovarian endometriosis cysts, but it is not possible to examine endometriosis adhesions and deep penetrating endometriosis. Some specialists use MRI, and CT scans to examine pelvic masses. But in the meantime, the best way to definitively diagnose endometriotic lesions is laparoscopic technique after confirmation of histological specimens (26, 27). However,


although laparoscopy is a valuable method for diagnosing and presenting a complete view of the lesions, it is not the first line of diagnosis due to its invasiveness, need for surgery and the high cost for patients (28, 29). The use of blood biomarkers through blood tests can also be an excellent alternative to help better diagnose endometriosis because it is less expensive for the patient and relatively non-invasive than laparoscopy. Changes in levels of proteins and microRNAs can be used in this regard (30). Also, research has shown that levels of cytokines, CA-125, and angiogenic and growth factors in women with endometriosis have changed compared to control samples, but they cannot be used as a definitive way to diagnose endometriosis (31, 32). It seems that the diagnosis of endometriosis varies according to the type and location of lesions, and it is better to use a combination of all the mentioned methods according to the patient's condition. As a result, more studies are needed in this field to say with certainty the role of techniques in the diagnosis of endometriosis (33).

### Management strategies

Due to the difficulty of definitive diagnosis and the chronicity of endometriosis, the management of this disease also requires more time and continuous follow-up (34, 35). Generally, depending on the patient's condition, the treatment is done in three ways; medication, surgery and ART. The first line of treatment is medicine, which includes hormonal and non-hormonal drugs, including analgesics that play an essential role in controlling pain caused by endometriosis. The most crucial analgesic agent is Non-steroidal Anti-inflammatory Drugs (NSAIDs). However, hormonal medications include a combination of oral contraceptives (COCs), gonadotropin-releasing hormone analogues (GnRHa) and progestin that help prevent the disease progression. During drug treatment, the disease process decreases, and the inflammation and pain caused by endometriotic lesions are reduced. It also costs less for the patient than surgery. On the other hand, the surgery, in addition to being associated with several risks and a recovery period, does not affect retrograde menstruation (36). However, because medical treatments reduce the patient's discomfort, they are not proper for all affected people. Because these drugs prevent ovulation by inhibiting hormonal fluctuations, thus they prevent pregnancy in females. On the other hand, these medications do not cure or eliminate endometriotic lesions but only reduce the pain and inflammation caused by this pathologic situation (37).

Although surgery has more costs and many side effects, it is the best way to eliminate endometriotic lesions and treat the pain. Studies have shown that removal of endometriotic lesions after surgery represented a significant role in the patient's fertility process and even increased spontaneous pregnancy rate (38, 39). Surgery is usually performed in two conservative and definitive ways. The difference between the two methods is excision of the uterus (hysterectomy) and one or both ovaries (oophorectomy) in a second way if needed. Also, in the first method, some lesions may remain due to the extended form of endometriotic lesions spread (6). Sometimes surgery can reduce the function of one or both ovaries, which is especially important in patients with bilateral involvement, advanced gestational age, a history of endometriosis, or infertility. Thus, the decision about surgery should be made with sensitivity and accuracy (5). Surgery procedures to remove endometriotic lesions are performed laparoscopically, except in a few cases where laparotomy is required due to the extensive lesions. However, it should always be considered that lesions are removed during surgery, while the cause of their occurrence is still present, which can explain the return of endometriotic lesions after surgery (40). Therefore, it is always necessary to apply medications after surgery to prevent the return of lesions (41).

Another way is the application of Assisted Reproductive Technologies (ART) to increase the fertility rate in infertile patients after endometriosis because the presence of endometriotic lesions reduces the chance of sperm contact with the ovum in the fallopian tubes. Thus, In Vitro Fertilization (IVF) can help fertility in these patients. However, in order to get better results in these patients, they should be treated with medication from 3 to 6 months before IVF (41). The strategies for the treatment of endometriosis in different conditions are depicted in Figure 2.



**Figure 2.** Therapeutic strategies for endometriosis. Treatment methods are varied in different conditions. In the case of pain, drug treatments are used, while assisted reproductive techniques are used in cases of infertility.

### Conclusion

Today, endometriosis, an inflammatory disease associated with chronic pelvic pain, is recognized as a social rather than an individual health problem because it affects 10% of all women worldwide. Also, its presence in the reproductive ages disrupts the process of fertilization and even causes infertility. There is still no definitive reason for endometriosis, but numerous findings have suggested the role of genetic, environmental, and inflammatory factors. Currently, the strongest theory for endometriosis is retrograde menstruation, which causes menstrual blood to return to the fallopian tubes and pelvic space, causing endometriotic lesions in these spaces. Depending on the location of lesions, they are divided into superficial peritoneal lesions, ovarian, and deep infiltrating endometriosis categories. Also, depending on the severity of the lesions, four stages are considered. However, in some cases, endometriosis may be caused by pelvic surgery, hormonal fertility treatments, menopause, and even pregnancy. Due to the release of many inflammatory factors in the pelvic cavity following endometriosis.

Also, the lack of fertility in patients who try for this purpose is another critical point that shows the need to treat and manage this disease as much as possible. Due to the existence of different phenotypes and the widespread forms of pelvic pain, the process of diagnosing has always been an excellent challenge for specialists, and it can be said that they use a diagnostic package and not just one way. A package includes non-invasive techniques such as asking about the patient's family history, urine tests, vaginal sampling and ultrasound examinations, and invasive laparoscopic techniques. Of course, laparoscopy provides a much better view for diagnosing the disease, but it is usually the last line of diagnosis because it is invasive and expensive. Treatment of endometriosis is not definitive and uses only one method, so gynaecologists use various treatments ranging from the prescription of hormonal medications to reduce pain, inflammation and prevention of secretion of hormones to surgical removal of lesions. It seems that in all fields, such as the definition, diagnosis, and treatment of the disease, there is always disagreement, given the disease's prominent role in women's health, so a consensus should be reached. Today, with the advancement of technology and extensive

studies done in various fields to better manage endometriosis, new markers have been identified that can make the diagnosis more accessible and faster. In this regard, we can mention interferon alpha 2 (IFN- $\alpha$  2) and tumor necrosis factor (TNF)-alpha inhibitors that have been tested in animal models. It is hoped that endometriosis will be diagnosed and treated more advanced in the future, and patients will be less likely to receive aggressive and stressful treatments. Therefore, we need more research on new strategies to help diagnose and treat endometriosis to advance women's health.

## References

1. Matalliotakis M, Zervou MI, Matalliotaki C, Rahmioglu N, Koumantakis G, Kalogiannidis I, Prapas I, Zondervan K, Spandidos DA, Matalliotakis I, Goulielmos GN. [The role of gene polymorphisms in endometriosis](https://doi.org/10.3892/mmr.2017.7398). Mol Med Rep 2017; 16(5): 5881-5886. <https://doi.org/10.3892/mmr.2017.7398>
2. Menni K, Facchetti L, Cabassa P. [Extragenital endometriosis: assessment with MR imaging. A pictorial review](https://doi.org/10.1259/bjr.20150672). Br J Radiol 2016; 89(1060): 20150672. <https://doi.org/10.1259/bjr.20150672>
3. Sapkota Y, Steinhorsdottir V, Morris AP, Fassbender A, Rahmioglu N, De Vivo I, Buring JE, Zhang F, Edwards TL, Jones S, Dorien O. [Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism](https://doi.org/10.1038/ncomms15539). Nat Commun 2017; 8(1): 1-2. <https://doi.org/10.1038/ncomms15539>
4. Koninckx PR, Ussia A, Adamyan L, Wattiez A, Gomel V, Martin DC. [Pathogenesis of endometriosis: the genetic/epigenetic theory](https://doi.org/10.1016/j.fertnstert.2018.10.013). Fertil Steril 2019; 111(2): 327-340. <https://doi.org/10.1016/j.fertnstert.2018.10.013>
5. Parasar P, Ozcan P, Terry KL. [Endometriosis: epidemiology, diagnosis and clinical management](https://doi.org/10.1007/s13669-017-0187-1). Curr Obstet Gynecol Rep 2017; 6(1): 34-41. <https://doi.org/10.1007/s13669-017-0187-1>
6. Chapron C, Marcellin L, Borghese B, Santulli P. [Rethinking mechanisms, diagnosis and management of endometriosis](https://doi.org/10.1038/s41574-019-0245-z). Nat Rev Endocrinol 2019; 15(11): 666-682. <https://doi.org/10.1038/s41574-019-0245-z>
7. Nnoaham KE, Hummelshoj L, Webster P, d'Hooghe T, de Cicco Nardone F, de Cicco Nardone C, Jenkinson C, Kennedy SH, Zondervan KT. [Reprint of: Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries](https://doi.org/10.1016/j.fertnstert.2011.05.090). Fertil Steril 2019; 112(4S1). <https://doi.org/10.1016/j.fertnstert.2011.05.090>
8. Bricou A, Batt RE, Chapron C. [Peritoneal fluid flow influences anatomical distribution of endometriotic lesions: why Sampson seems to be right](https://doi.org/10.1016/j.ejogrb.2008.01.014). Eur J Obstet Gynecol Reprod Biol 2008; 138(2): 127-134. <https://doi.org/10.1016/j.ejogrb.2008.01.014>
9. Vercellini P, Viganò P, Somigliana E, Fedele L. [Endometriosis: pathogenesis and treatment](https://doi.org/10.1038/nrendo.2013.255). Nat Rev Endocrinol 2014; 10(5): 261. <https://doi.org/10.1038/nrendo.2013.255>
10. Falconer H, D'Hooghe T, Fried G. [Endometriosis and genetic polymorphisms](https://doi.org/10.1097/01.ogx.0000279293.60436.60). Obstet Gynecol Surv 2007; 62(9): 616-628. <https://doi.org/10.1097/01.ogx.0000279293.60436.60>
11. Lowe WL, Reddy TE. [Genomic approaches for understanding the genetics of complex disease](https://doi.org/10.1101/gr.190603.115). Genome Res 2015; 25(10): 1432-1441. <https://doi.org/10.1101/gr.190603.115>
12. Treloar SA, Wicks J, Nyholt DR, Montgomery GW, Bahlo M, Smith V, Dawson G, Mackay IJ, Weeks DE, Bennett ST, Carey A. [Genomewide linkage study in 1,176 affected sister pair families identifies a significant susceptibility locus for endometriosis on chromosome 10q26](https://doi.org/10.1086/432960). Am J Hum Genet 2005; 77(3): 365-376. <https://doi.org/10.1086/432960>
13. Smarr MM, Kannan K, Louis GM. [Endocrine disrupting chemicals and endometriosis](https://doi.org/10.1016/j.fertnstert.2016.06.034). Fertil Steril 2016; 106(4): 959-966. <https://doi.org/10.1016/j.fertnstert.2016.06.034>
14. Yang M, Mercy AO, Efehi N, Venera M, Liu X, Ebadi AG, Toughani M. [Evaluation of Physicochemical and DPPH· Cleaning Activity of Ultrasonic Assisted Extraction of Polysaccharide from \*Leonurus japonicas\*](https://doi.org/10.37358/RC.20.4.8101). Rev Chim 2020; 71(4): 601-614. <https://doi.org/10.37358/RC.20.4.8101>
15. Galvankar M, Singh N, Modi D. [Estrogen is essential but not sufficient to induce endometriosis](https://doi.org/10.1007/s12038-017-9687-4). J Biosci 2017; 42(2): 251-263. <https://doi.org/10.1007/s12038-017-9687-4>

16. Streuli I, Gaitzsch H, Wenger JM, Petignat P. **Endometriosis after menopause: physiopathology and management of an uncommon condition.** *Climacteric* 2017; 20(2): 138-143. <https://doi.org/10.1080/13697137.2017.1284781>
17. Tomassetti C, D'Hooghe T. **Endometriosis and infertility: Insights into the causal link and management strategies.** *Best Pract Res Clin Obstet Gynaecol* 2018; 51: 25-33. <https://doi.org/10.1016/j.bpobgyn.2018.06.002>
18. Liang H, Khan ZI, Ahmad K, Nisar A, Mahmood Q, Ebadi AG, Toughani M. **Assessment of Zinc and Nickel Profile of Vegetables Grown in Soil Irrigated with Sewage Water.** *Rev Chim* 2020; 71(4): 500-511. <https://doi.org/10.37358/RC.20.4.8092>
19. Jerman LF, Hey-Cunningham AJ. **The role of the lymphatic system in endometriosis: a comprehensive review of the literature.** *Biol Reprod* 2015; 92(3): 64-61. <https://doi.org/10.1095/biolreprod.114.124313>
20. Vercellini P, Consonni D, Dridi D, Bracco B, Frattaruolo MP, Somigliana E. **Uterine adenomyosis and in vitro fertilization outcome: a systematic review and meta-analysis.** *Hum Reprod* 2014b; 29(5): 964-977. <https://doi.org/10.1093/humrep/deu041>
21. Okada H, Tsuzuki T, Murata H. **Decidualization of the human endometrium.** *Reprod Med Biol* 2018; 17(3): 220-227. <https://doi.org/10.1002/rmb2.12088>
22. Yang M, Efehi N, Jin Y, Zhang Q, Ebadi AG, Toughani M. **Hot Water Extraction of Crude Polysaccharide from *Codonopsis pilosula* and Determination of the Rheological Properties.** *Rev Chim* 2020; 71(5): 441-449. <https://doi.org/10.37358/RC.20.5.8155>
23. Lebovic DI, Mueller MD, Taylor RN. **Immunobiology of endometriosis.** *Fertil Steril.* 2001; 75: 1-0. [https://doi.org/10.1016/S0015-0282\(00\)01630-7](https://doi.org/10.1016/S0015-0282(00)01630-7)
24. Howard FM. **Endometriosis and mechanisms of pelvic pain.** *J Minim Invasive Gynecol* 2009; 16(5): 540-550. <https://doi.org/10.1016/j.jmig.2009.06.017>
25. Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, Stratton P. **Differences in characteristics among 1,000 women with endometriosis based on extent of disease.** *Fertil Steril* 2008; 89(3): 538-545. <https://doi.org/10.1016/j.fertnstert.2007.03.069>
26. Wang Y, Dou S, Zhang Q, Ebadi AG, Chen J, Toughani M. **Bacterial Separation and Community Diversity Analysis of Petroleum Contaminated Soil in Yumen Oilfield.** *Rev Chim* 2020; 71(3): 595-607. <https://doi.org/10.37358/RC.20.3.8035>
27. Chapron C, Lang JH, Leng JH, Zhou Y, Zhang X, Xue M, Popov A, Romanov V, Maisonobe P, Cabri P. **Factors and Regional Differences Associated with Endometriosis: A Multi-Country, Case–Control Study.** *Adv Ther.* 2016; 33(8):1385-407. <https://doi.org/10.1007/s12325-016-0366-x>
28. Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E. **ESHRE guideline for the diagnosis and treatment of endometriosis.** *Hum Reprod* 2005; 20(10): 2698-2704. <https://doi.org/10.1093/humrep/dei135>
29. Bao S, Ebadi A, Toughani M, Dalle J, Maselena A, Yıldızbaşı A. **A new method for optimal parameters identification of a PEMFC using an improved version of Monarch Butterfly Optimization Algorithm.** *Int J Hydrogen Energy* 2020; 45(35): 17882-17892. <https://doi.org/10.1016/j.ijhydene.2020.04.256>
30. Nisenblat V, Bossuyt PM, Shaikh R, Farquhar C, Jordan V, Scheffers CS, Mol BW, Johnson N, Hull ML. **Blood biomarkers for the non-invasive diagnosis of endometriosis.** *Cochrane Database Syst Rev.* 2016(5). <https://doi.org/10.1002/14651858.CD012179>
31. Fassbender A, Vodolazkaia A, Saunders P, Lebovic D, Waelkens E, De Moor B, D'Hooghe T. **Biomarkers of endometriosis.** *Fertil Steril* 2013; 99(4): 1135-1145. <https://doi.org/10.1016/j.fertnstert.2013.01.097>
32. Petraglia F, Hornung D, Seitz C, Faustmann T, Gerlinger C, Luisi S, Lazzeri L, Strowitzki T. **Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment.** *Archives Gynecol Obstet* 2012; 285(1): 167-173. <https://doi.org/10.1007/s00404-011-1941-7>



33. Yang M, Abdalrahman H, Sonia U, Mohammed A, Vestine U, Wang M, Ebadi AG, Toughani M. [The application of DNA molecular markers in the study of Codonopsis species genetic variation, a review.](#) Cell Mol Biol 2020; 2: 23-30. <https://doi.org/10.14715/cmb/2020.66.2.3>
34. Santulli P, Marcellin L, Tosti C, Chouzenoux S, Cerles O, Borghese B, Batteux F, Chapron C. [MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?](#) Expert Opin Ther Targets 2015; 19(11): 1465-1483. <https://doi.org/10.1517/14728222.2015.1090974>
35. Ferrero S, Alessandri F, Racca A, Maggiore UL. [Treatment of pain associated with deep endometriosis: alternatives and evidence.](#) Fertil Steril 2015; 104(4): 771-792. <https://doi.org/10.1016/j.fertnstert.2015.08.031>
36. Jacobson TZ, Duffy JM, Barlow DH, Farquhar C, Koninckx PR, Olive D. [Laparoscopic surgery for subfertility associated with endometriosis.](#) Cochrane Database Syst Rev 2002; (4): CD001398. <https://doi.org/10.1002/14651858.CD001398.pub2>
37. De Ziegler D, Borghese B, Chapron C. [Endometriosis and infertility: pathophysiology and management.](#) Lancet 2010; 376(9742): 730-738. [https://doi.org/10.1016/S0140-6736\(10\)60490-4](https://doi.org/10.1016/S0140-6736(10)60490-4)
38. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignani PG. [Surgery for endometriosis-associated infertility: a pragmatic approach.](#) Hum Reprod 2009; 24(2): 254-269. <https://doi.org/10.1093/humrep/den379>
39. Wen L, Zhang Y, Yang B, Han F, Ebadi AG, Toughani M. [Knockdown of Angiopoietin-like protein 4 suppresses the development of colorectal cancer.](#) Cell Mol Biol 2020; 66(5): 117-124. <https://doi.org/10.14715/cmb/2020.66.5.21>
40. Lazzeri L, Di Giovanni A, Exacoustos C, Tosti C, Pinzauti S, Malzoni M, Petraglia F, Zupi E. [Preoperative and postoperative clinical and transvaginal ultrasound findings of adenomyosis in patients with deep infiltrating endometriosis.](#) Reprod Sci 2014; 21(8):1027-1033. <https://doi.org/10.1177/1933719114522520>
41. Sallam HN, Garcia-Velasco JA, Dias S, Arici A, Abou-Setta AM. [Long-term pituitary down-regulation before in vitro fertilization \(IVF\) for women with endometriosis.](#) Cochrane Database Syst Rev 2006 Jan 25; (1): CD004635. <https://doi.org/10.1002/14651858.CD004635.pub2>



© 2021 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**How to cite this paper:**

Bagheri M, Zohre-Vand F, Hamzeie M, Arji Roudsari B. [Endometriosis as female reproductive system disorder: mechanisms, diagnosis and clinical management.](#) Cent Asian J Med Pharm Sci Innov 2021; 1(4): 185-193.